Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 15:392:578369.
doi: 10.1016/j.jneuroim.2024.578369. Epub 2024 May 14.

Electroconvulsive therapy in N-methyl-d-aspartate receptor encephalitis: A retrospective cohort and scoping review of literature

Melissa A Wright  1 , Mar Guasp  2 , Christian Lachner  3 , Gregory S Day  4 , Grace Gombolay  5 , Maarten J Titulaer  6 , Stacey L Clardy  7
Affiliations

Electroconvulsive therapy in N-methyl-d-aspartate receptor encephalitis: A retrospective cohort and scoping review of literature

Melissa A Wright et al. J Neuroimmunol. .

Abstract

Neuropsychiatric symptoms in N-methyl-d-aspartate receptor encephalitis (NMDARE) have led some to pursue empiric trials of electroconvulsive therapy (ECT). A scoping review identified 39 patients diagnosed with NMDARE undergoing ECT. Separately, a retrospective cohort was reviewed to characterize 21 patients. Clinical improvement was attributed to ECT in 49% of patients in the scoping review and 19% of patients in the retrospective cohort; timing of immunotherapies was a confounding factor. Worsening of clinical course following ECT was reported in 28% of patients in the scoping review and 38% of patient in the retrospective review. There is currently insufficient data supporting a beneficial effect of ECT in NMDARE.

Keywords: Autoimmune encephalitis; Catatonia; Electroconvulsive therapy; N-methyl-d-aspartate receptor encephalitis; Neuropsychiatric symptoms.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest None.

Figures

Figure 1:
Figure 1:. PRISMA Flow Diagram for Study Selection.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram showing study selection and reasons for omission of excluded studies.
Figure 2:
Figure 2:
Reported Response to ECT
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Abbatemarco JR, Rodenbeck SJ, Day GS, Titulaer MJ, Yeshokumar AK, Clardy SL, 2021. Autoimmune Neurology: The Need for Comprehensive Care. Neurology - Neuroimmunol Neuroinflammation 8, e1033. 10.1212/nxi.0000000000001033 - DOI - PMC - PubMed
    1. Albrecht J, Meves A, Bigby M, 2005. Case reports and case series from Lancet had significant impact on medical literature. J Clin Epidemiol 58, 1227–1232. 10.1016/j.jclinepi.2005.04.003 - DOI - PubMed
    1. Al-Diwani A, Handel A, Townsend L, Pollak T, Leite MI, Harrison PJ, Lennox BR, Okai D, Manohar SG, Irani SR, 2019. The psychopathology of NMDAR-antibody encephalitis in adults: a systematic review and phenotypic analysis of individual patient data. Lancet Psychiatry 6, 235–246. 10.1016/s2215-0366(19)30001-x - DOI - PMC - PubMed
    1. Andrade C, Bolwig TG, 2014. Electroconvulsive Therapy, Hypertensive Surge, Blood-Brain Barrier Breach, and Amnesia. J Ect 30, 160–164. 10.1097/yct.0000000000000133 - DOI - PubMed
    1. Balu R, McCracken L, Lancaster E, Graus F, Dalmau J, Titulaer MJ, 2018. A score that predicts 1-year functional status in patients with anti-NMDA receptor encephalitis. Neurology 92, 10.1212/WNL.0000000000006783. 10.1212/wnl.0000000000006783 - DOI - PMC - PubMed

Publication types

LinkOut - more resources